These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

393 related items for PubMed ID: 20067326

  • 1. Cost effectiveness of a lidocaine 5% medicated plaster compared with pregabalin for the treatment of postherpetic neuralgia in the UK: a Markov model analysis.
    Ritchie M, Liedgens H, Nuijten M.
    Clin Drug Investig; 2010; 30(2):71-87. PubMed ID: 20067326
    [Abstract] [Full Text] [Related]

  • 2. Cost-effectiveness analysis of a lidocaine 5% medicated plaster compared with gabapentin and pregabalin for treating postherpetic neuralgia: a german perspective.
    Liedgens H, Hertel N, Gabriel A, Nuijten M, Dakin H, Mitchell S, Nautrup BP.
    Clin Drug Investig; 2008; 28(9):583-601. PubMed ID: 18666805
    [Abstract] [Full Text] [Related]

  • 3. Cost-effectiveness of a lidocaine 5% medicated plaster relative to gabapentin for postherpetic neuralgia in the United Kingdom.
    Dakin H, Nuijten M, Liedgens H, Nautrup BP.
    Clin Ther; 2007 Jul; 29(7):1491-507. PubMed ID: 17825701
    [Abstract] [Full Text] [Related]

  • 4. Efficacy and safety of 5% lidocaine (lignocaine) medicated plaster in comparison with pregabalin in patients with postherpetic neuralgia and diabetic polyneuropathy: interim analysis from an open-label, two-stage adaptive, randomized, controlled trial.
    Baron R, Mayoral V, Leijon G, Binder A, Steigerwald I, Serpell M.
    Clin Drug Investig; 2009 Jul; 29(4):231-41. PubMed ID: 19301937
    [Abstract] [Full Text] [Related]

  • 5. Cost-effectiveness analysis of 5% lidocaine-medicated plaster compared with pregabalin for the treatment of post-herpetic neuralgia in China.
    Zeng F, Wang M, Zhang D.
    Ann Palliat Med; 2021 Apr; 10(4):4493-4501. PubMed ID: 33894728
    [Abstract] [Full Text] [Related]

  • 6. Cost-effectiveness analysis of a new 8% capsaicin patch compared to existing therapies for postherpetic neuralgia.
    Armstrong EP, Malone DC, McCarberg B, Panarites CJ, Pham SV.
    Curr Med Res Opin; 2011 May; 27(5):939-50. PubMed ID: 21375358
    [Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8. Cost-utility of pregabalin as add-on to usual care versus usual care alone in the management of peripheral neuropathic pain in Belgium.
    Chevalier P, Lamotte M, Van Campenhout H, Eyckerman R, Annemans L.
    J Med Econ; 2013 May; 16(5):596-605. PubMed ID: 23409950
    [Abstract] [Full Text] [Related]

  • 9. Post-herpetic neuralgia: 5% lidocaine medicated plaster, pregabalin, or a combination of both? A randomized, open, clinical effectiveness study.
    Rehm S, Binder A, Baron R.
    Curr Med Res Opin; 2010 Jul; 26(7):1607-19. PubMed ID: 20429825
    [Abstract] [Full Text] [Related]

  • 10. Comparing healthcare costs of Medicaid patients with postherpetic neuralgia (PHN) treated with lidocaine patch 5% versus gabapentin or pregabalin.
    Kirson NY, Ivanova JI, Birnbaum HG, Wei R, Kantor E, Puenpatom RA, Ben-Joseph RH, Summers KH.
    J Med Econ; 2010 Jul; 13(3):482-91. PubMed ID: 20684669
    [Abstract] [Full Text] [Related]

  • 11. 5% lidocaine-medicated plaster vs other relevant interventions and placebo for post-herpetic neuralgia (PHN): a systematic review.
    Wolff RF, Bala MM, Westwood M, Kessels AG, Kleijnen J.
    Acta Neurol Scand; 2011 May; 123(5):295-309. PubMed ID: 21039364
    [Abstract] [Full Text] [Related]

  • 12. 5% lidocaine medicated plaster in elderly patients with postherpetic neuralgia: results of a compassionate use programme in France.
    Clère F, Delorme-Morin C, George B, Navez M, Rioult B, Tiberghien-Chatelain F, Ganry H.
    Drugs Aging; 2011 Sep 01; 28(9):693-702. PubMed ID: 21913735
    [Abstract] [Full Text] [Related]

  • 13. Efficacy and safety of combination therapy with 5% lidocaine medicated plaster and pregabalin in post-herpetic neuralgia and diabetic polyneuropathy.
    Baron R, Mayoral V, Leijon G, Binder A, Steigerwald I, Serpell M.
    Curr Med Res Opin; 2009 Jul 01; 25(7):1677-87. PubMed ID: 19480610
    [Abstract] [Full Text] [Related]

  • 14. Cost-effectiveness of pregabalin for the management of neuropathic pain associated with diabetic peripheral neuropathy and postherpetic neuralgia: a Canadian perspective.
    Tarride JE, Gordon A, Vera-Llonch M, Dukes E, Rousseau C.
    Clin Ther; 2006 Nov 01; 28(11):1922-34. PubMed ID: 17213013
    [Abstract] [Full Text] [Related]

  • 15. A cost-effectiveness comparison of desipramine, gabapentin, and pregabalin for treating postherpetic neuralgia.
    O'Connor AB, Noyes K, Holloway RG.
    J Am Geriatr Soc; 2007 Aug 01; 55(8):1176-84. PubMed ID: 17661955
    [Abstract] [Full Text] [Related]

  • 16. Topical 5% lidocaine (lignocaine) medicated plaster treatment for post-herpetic neuralgia: results of a double-blind, placebo-controlled, multinational efficacy and safety trial.
    Binder A, Bruxelle J, Rogers P, Hans G, Bösl I, Baron R.
    Clin Drug Investig; 2009 Aug 01; 29(6):393-408. PubMed ID: 19432499
    [Abstract] [Full Text] [Related]

  • 17. Cost effectiveness of pregabalin in the treatment of fibromyalgia from a UK perspective.
    Choy E, Richards S, Bowrin K, Watson P, Lloyd A, Sadosky A, Zlateva G.
    Curr Med Res Opin; 2010 Apr 01; 26(4):965-75. PubMed ID: 20178405
    [Abstract] [Full Text] [Related]

  • 18. Health economic evidence of 5% lidocaine medicated plaster in post-herpetic neuralgia.
    Liedgens H, Obradovic M, Nuijten M.
    Clinicoecon Outcomes Res; 2013 Nov 25; 5():597-609. PubMed ID: 24348056
    [Abstract] [Full Text] [Related]

  • 19. Lidocaine 5% medicated plaster: a review of its use in postherpetic neuralgia.
    Garnock-Jones KP, Keating GM.
    Drugs; 2009 Oct 22; 69(15):2149-65. PubMed ID: 19791831
    [Abstract] [Full Text] [Related]

  • 20. Pregabalin versus gabapentin in the management of peripheral neuropathic pain associated with post-herpetic neuralgia and diabetic neuropathy: a cost effectiveness analysis for the Greek healthcare setting.
    Athanasakis K, Petrakis I, Karampli E, Vitsou E, Lyras L, Kyriopoulos J.
    BMC Neurol; 2013 Jun 04; 13():56. PubMed ID: 23731598
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 20.